Objectives: This study is designed to explore factors associated with death in newborns with persistent pulmonary hypertension (PPHN). Methods: The clinical data of PPHN cases in the past ten years from a neonatal center in China were retrospectively collected and analyzed, and the death-related factors attributable to PPHN were analyzed by binary stepwise logistic regression analysis. Results: A total of 161 neonates with PPHN were included in this study, with a mortality rate of 18.0% (29/161). Multivariate binary logistic regression analysis indicated that cesarean delivery was negatively associated with death in infants with PPHN (adjusted odds ratio [OR] = 0.289, 95% confidence interval [CI] 0.104 – 0.803), while premature rupture of membranes (PROM) (adjusted OR = 4.032, 95% CI 1.32 - 12.32), congenital lung developmental abnormalities/congenital diaphragmatic hernia (CDH) (adjusted OR = 12.65, 95% CI 1.088 – 147.068), respiratory distress syndrome (RDS) (adjusted OR = 4.802, 95% CI 1.512 – 15.251), inhaled nitric oxide (iNO) (adjusted OR = 12.377, 95% CI 3.22 – 47.576) and norepinephrine (adjusted OR = 2.891, 95% CI 1.03 – 8.118) were the independent factors associated with a higher risk of death from PPHN. Conclusions: Caesarean delivery with medical indication is an independent protective factor against death in neonates with PPHN. PROM, congenital lung developmental abnormalities/CDH, RDS, iNO, and norepinephrine were independent death-related factors in neonates with PPHN.
Objective: To evaluate the analgesic effect of Comdrugcide in the treatment of cancer pain.Methods: 69 cancer patients with moderate and severe pain were divided randomly to receive Comdrugcide 50～150ml q8h(n=36) or Galake 1～2# q6h(n=33) for seven days.Results:The total remission rate of Comdrugcide on cancer pain was 83.3% and those for moderate and severe pain were 92.6% and 55.6%, respectively,similar to those of Galake. It had better quality of life, few and slighter side-effects.Conclusion: Comdrugcide is an effective and safe agent for treatment of moderate cancer pain.
Abstract A small population of cells with stem cell‐like properties in prostate cancer ( PC a), called prostate cancer stem cells (Pr CSC s) or prostate stemness‐high cancer cells, displays highly tumorigenic and metastatic features and may be responsible for the therapy resistance. A small molecule, napabucasin ( BBI 608), recently have been identified with suppression of stemness‐high cancer cells in a variety of cancers. However, the effects of napabucasin on PC a cells as well as Pr CSC s isolated from PC a cells have not yet been defined. The effect of napabucasin on PC a cells in cell proliferation, colony formation, and cell migration in vitro were measured by MTS , colony formation assay, and Transwell, respectively. Flow cytometry was employed to evaluate cell cycle and cell apoptosis, and the effect on tumorigenesis in vivo was examined by tumor growth assays. Furthermore, the role of napabucasin on self‐renewal and survival of Pr CSC s was evaluated by their ability to grow spheres and cell viability assay, respectively. Western Blot and qRT ‐ PCR were used to determine the effect of napabucasin on the expressions of stemness markers. Decrease in cell viability, colony formation, migration, and survival with cell cycle arrest, higher sensitivity to docetaxel in vitro, and repressed tumorigenesis in vivo was observed upon napabucasin treatment. More importantly, napabucasin can obviously inhibit spherogenesis and even kill Pr CSC s in vitro. Downregulation of stemness markers was observed after Pr CSC s were treated with napabucasin. This study demonstrates that napabucasin may be a novel approach in the treatment of advanced PC a, specifically for castration‐resistant prostate cancer ( CRPC ).
Doxorubicin (DOX), the first-line chemotherapy for bladder cancer, usually induces side effects. We previously demonstrated that green tea polyphenol EGCG had potent anti-tumor effect in bladder cancer via down regulation of NF-κB. This study aimed to investigate the additive/synergistic effect EGCG and DOX against bladder cancer. Our results demonstrated that the combined use of DOX and EGCG inhibited T24 and SW780 cell proliferation. EGCG enhanced the apoptosis induction effect of DOX in both SW780 and T24 cells and resulted in significant differences. Besides, EGCG promoted the inhibitory effect of DOX against bladder cancer cell migration. In addition, the in vivo results demonstrated that DOX in combination with EGCG showed the most potent anti-tumor effects among DOX, EGCG and DOX+EGCG treatment groups. Further mechanistic studies determined that the combination of DOX and EGCG inhibited phosphorylated NF-κB and MDM2 expression, and up-regulated p53 expression in tumor, as assessed by western blot and immunohistochemistry. Western blot in SW780 cells also confirmed that the combined use of EGCG and DOX caused significant increase in p53, p21, and cleaved-PARP expression, and induced significant inhibition in phosphorylated NF-κB and MDM2. When NF-κB was inhibited, the expression of p53 and p-MDM2 were changed, and the combination of DOX and EGCG showed no obvious effect in transwell migration and cell viability. In conclusion, the novel application of chemotherapy DOX and EGCG demonstrated potent anti-tumor, anti-migration and anti-proliferation effects against bladder cancer. EGCG enhanced the anti-tumor effect of DOX in bladder cancer via NF-κB/MDM2/p53 pathway, suggesting the potential clinical application against bladder cancer patients.
Objective:To compare the effects and side effects of ropivacaine and racemic bupiacaine in epidural analgesia after cesarean section.Methods:Fifty full-terms,nulliparous women undergoing cesarean section under eqidural anesthesia ware enrolled in this randomized double-blind study and were divided into ropivacaine group and racemic bupiacaine group.After operation,the patients were randomized to receive 1.5 ropivacaine(group R,n=25)or 0.125 bupivacaine(group B,n=25)for patient-controlled epidural analgesia(PCEA).The PCEA solution for the 2 groups contained fentany1 2 μg/ml.The visual analog scale(VAS),Bromage motor scale score,cardiovascular variables and side effects were recorded within 48 hours after operation.Results:There was no significant difference in VAS scores;group R was lower in extremity locomotion blockage and was superior in muscle force recovery.Conclusions:PCEA with 0.15 ropivacaine containing fentanyl 2 μg/ml provides adequate pain relief after cesarean section with little noxious or side effects.
Objective:To observe the clinical effects of low concentration of ropivacaine(0.25%) on cervical plexus block.Methods:Forty patients undergoing thyroid adenoma removal were randomly divided into two groups:group R(n=20) were injected 0.25% ropivacaine in cervical plexus;group L(n=20) were injected 1% lidocaine and 0.19% bupivacaine in cervical plexus.The clinical effects,complications,recovery time and influence on cardiovascular system were observed.Results:There was no significant difference in the onset time between the two groups(P0.05).The recovery from,hoarseness was quicker in group R than in group L(P0.05).Conclusions:It is preferable to use 0.25% ropivacaine in cervical plexus block in regard to clinical effects and safety.
Objective:To evaluate the feasibility and clinical results of postoperative analgesia by incisional infiltration of lornoxicam. Methods:Forty-five patients with head and neck surgery were chosen.Five patients required postoperative analgesia and the remaining were divided into group A and group B with 20 cases each.Group A:8 mg lornoxicam dissolved in 0.9% 20 ml normal saline,before suture,patients were injected by the layers of tissue within the incision;Group B:No special treatment,the incision was sutured directly;Group C:48 mg lornoxicam combined with 100 μg sufentanil dissolved in 0.9% saline to 100 ml,postoperative patient-controlled intravenous analgesia.Record pain score,drug-related side effects,wound healing and patient satisfaction immediately,1,6,12,24 hours after each operation. Results:Pain score of group A,C were significantly lighter than group B(P0.01),1 case of group C postoperative vomiting.Three wounds were Ⅰhealed.Three satisfaction surveys are very satisfied and satisfied. Conclusions:Lornoxicam promised a good analgesic effect of infiltration and could be used for superficial incision for postoperative analgesia.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)